top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Frame 1410148109.png
Frame 100000825.png
Frame i1000008267.png
Frame 1410148108.png
Frame 10000082699.png
Fra 1000008266.png
Frame 1000i008268.png
Frame 1410148110.png
Frame 100070.png
Frame 1410148111.png
valve.png

Agatston-2.0: AI-CAC Reclassifies CHD Risk Within Conventional CAC 1–99 — Part III

2 days ago
2 min read

Submitted manuscript | Original research review

Agatston-2.0 is an AI-enabled approach to coronary artery calcium (CAC) CT that characterizes plaque distribution and density, aiming to add risk information beyond the conventional Agatston score. This Part III analysis examined whether the approach could further stratify adults whose conventional CAC scores were 1–99.

Study design

The pooled observational analysis included 1,542 participants from MESA (n=1,142) and the Framingham Heart Study (n=400) with CAC 1–99 below the standardized 75th percentile. AI-CAC features included a distribution index (number of plaques × vessels involved), a hyperdensity index, and relative-density measures. Coronary heart disease (CHD) events were assessed during follow-up.

Key findings

Over a median 12.5 years, 151 CHD events occurred. Ten-year cumulative CHD incidence varied across AI-CAC phenotypes: 2.2% for focal, dense calcium; 4.8% for focal calcium; 11.1% for diffuse, multivessel calcium; 14.8% for diffuse, low-density calcium; and 20.9% when the higher-risk phenotype was accompanied by an enlarged heart or aorta. Adding distribution and hyperdensity indices to the conventional score improved discrimination (C-index 0.562 to 0.625; optimism-corrected NRI 0.279).

Interpretation

The findings suggest that AI-derived plaque patterns and density may distinguish substantially different risk profiles within the conventional CAC 1–99 group. As an observational cohort analysis, the study supports further validation and does not establish that AI-CAC-guided treatment improves outcomes.

Abstract

Background: Conventional CAC scoring has limited ability to distinguish risk among people with CAC scores below 100. Objective: To evaluate whether Agatston-2.0 AI-CAC improves CHD risk stratification beyond conventional CAC. Methods: Pooled MESA and Framingham cohort analysis of 1,542 adults with CAC 1–99 below the standardized 75th percentile; AI-CAC quantified plaque distribution and density. Results: Across 151 CHD events over median 12.5 years, 10-year CHD incidence ranged from 2.2% in a focal, dense phenotype to 20.9% with diffuse, multivessel calcium plus enlarged heart/aorta. Adding distribution and hyperdensity indices improved C-index from 0.562 to 0.625. Conclusions: AI-CAC phenotyping may identify lower- and higher-risk subgroups within CAC 1–99 and merits external validation.

Status: Submitted to the American Journal of Preventive Cardiology. Manuscript AJPC-D-26-01214. The full manuscript is not attached.

Download the abstract

Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png
iScreen Shoter - 20261104171348520.jpg

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page